{"filing":{"accession_number":"0001193125-26-425243","cik":"0001674416","ticker":"CRSP","company_name":"CRISPR Therapeutics AG","form":"8-K","filing_date":"2026-10-19","report_date":"2026-10-19","primary_document":"crsp-20261019.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1674416/000119312526425243/crsp-20261019.htm"},"events":[{"id":36078,"run_id":33263,"accession_number":"0001193125-26-425243","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"summary":"The filing discloses the appointment of Andrew J. Silver as Chief Financial Officer of CRISPR Therapeutics AG effective October 19, 2026, along with detailed employment terms including a $515,000 annual salary, 45% target bonus, and a 25,000 RSU grant. While the section also mentions the concurrent resignation of prior CFO Raju Prasad, the principal disclosed action centers on the appointment of the new CFO and his compensatory arrangements, making exec_appointment the most salient classification. This is material to investors as it involves a key executive officer position at a major biotechnology company.","company_name":"CRISPR Therapeutics AG","ticker":"CRSP","filing_date":"2026-10-19","form":"8-K","submitted_at":null,"items":[{"id":40358,"accession_number":"0001193125-26-425243","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The filing discloses the appointment of Andrew J. Silver as Chief Financial Officer of CRISPR Therapeutics AG effective October 19, 2026, along with detailed employment terms including a $515,000 annual salary, 45% target bonus, and a 25,000 RSU grant. While the section also mentions the concurrent resignation of prior CFO Raju Prasad, the principal disclosed action centers on the appointment of the new CFO and his compensatory arrangements, making exec_appointment the most salient classification. This is material to investors as it involves a key executive officer position at a major biotechnology company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-19T20:12:37.149745+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":40358,"accession_number":"0001193125-26-425243","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The filing discloses the appointment of Andrew J. Silver as Chief Financial Officer of CRISPR Therapeutics AG effective October 19, 2026, along with detailed employment terms including a $515,000 annual salary, 45% target bonus, and a 25,000 RSU grant. While the section also mentions the concurrent resignation of prior CFO Raju Prasad, the principal disclosed action centers on the appointment of the new CFO and his compensatory arrangements, making exec_appointment the most salient classification. This is material to investors as it involves a key executive officer position at a major biotechnology company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-19T20:12:37.149745+00:00","company_name":"CRISPR Therapeutics AG","ticker":"CRSP","filing_date":"2026-10-19"}]}